本维莫德通过AHR/ARNT通路抑制IL-4/IL-13诱导的紧密连接损伤
生物信息学分析及12例特应性皮炎患者与12例健康对照免疫组化显示,特应性皮炎皮损中CLDN1、CLDN4和OCLN表达降低。体外研究显示IL-4和IL-13经Jak-STAT6通路下调HaCaT细胞及人原代角质形成细胞中CLDN1、CLDN4和OCLN表达并增加4-kDa葡聚糖旁细胞通量。本维莫德通过AHR/ARNT通路上调CLDN4和OCLN,诱导NRF2核转位并减少ROS产生,从而抑制IL-4/IL-13诱导的CLDN1下调和STAT6磷酸化。
要点
- 特应性皮炎皮损中CLDN1、CLDN4和OCLN表达降低。
- IL-4和IL-13经Jak-STAT6通路下调角质形成细胞紧密连接蛋白并增加旁细胞通量。
- 本维莫德通过AHR/ARNT通路上调CLDN4和OCLN,抑制IL-4/IL-13诱导的CLDN1下调和STAT6磷酸化。
核心结论
- Th2细胞因子参与紧密连接损伤,本维莫德可抑制这些效应。
研究设计与样本
- 生物信息学分析联合12例特应性皮炎患者与12例健康对照的免疫组化染色,以及HaCaT细胞和人原代角质形成细胞的体外研究。
主要发现
- 特应性皮炎皮损中CLDN1、CLDN4和OCLN表达较健康对照降低。
- IL-4和IL-13下调HaCaT细胞中CLDN1、CLDN4和OCLN表达以及人原代角质形成细胞中CLDN4和OCLN表达。
- 该效应经Jak-STAT6信号通路介导,并增加4-kDa葡聚糖旁细胞通量。
- 本维莫德通过AHR/ARNT通路上调CLDN4和OCLN。
- 本维莫德诱导NRF2核转位并减少角质形成细胞ROS产生,抑制IL-4/IL-13诱导的CLDN1下调和STAT6磷酸化。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tight junctions are involved in skin barrier functions. In this study, the expression of CLDN1, CLDN4, and OCLN was found to decrease in skin lesions of atopic dermatitis by bioinformatics analysis. Immunohistochemistry staining in skin specimens from 12 patients with atopic dermatitis and 12 healthy controls also showed decreased CLDN1, CLDN4, and OCLN expression in atopic dermatitis lesions. In vitro studies showed that IL-4 and IL-13 downregulated CLDN1, CLDN4, and OCLN expression in HaCaT cells as well as CLDN4 and OCLN expression in human primary keratinocytes. This effect, which was mediated through the Jak-signal transducer and activator of transcription 6 signaling pathway, increased paracellular flux of 4-kDa dextran. Benvitimod, a new drug for atopic dermatitis, upregulated CLDN4 and OCLN through the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator pathway. Benvitimod induced nuclear translocation of NRF2 and reduced production of ROS in keratinocytes, thus inhibiting IL-4-/IL-13-induced CLDN1 downregulation and signal transducer and activator of transcription 6 phosphorylation. These results indicate that T helper 2 cytokines are involved in tight junction impairment, and benvitimod can inhibit these effects.
引用
- Wang X, Mao D, Jia J, et al. Benvitimod Inhibits IL-4- and IL-13-Induced Tight Junction Impairment by Activating AHR/ARNT Pathway and Inhibiting STAT6 Phosphorylation in Human Keratinocytes. J Invest Dermatol. 2023. PMID: 37734479. doi:10.1016/j.jid.2023.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。